Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval - Eli Lilly ( NYSE:LLY ) , Hims & Hers Health ( NYSE:HIMS )
Novo Nordisk NVO has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children aged 6 to 12 using the injectable pens over a year compared to a placebo group.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
15 %
|
|
HIMS
|
Neutral
|
15 %
|
|
NVO
|
Neutral
|
37 %
|
